Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTEUS: Apalutamide in High-risk Localized or Locally Advanced Prostate Cancer
NCT03767244Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2019
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 18
01
Overview
A Phase 3 trial of apalutamide in prostate cancer (PCa), sponsored by Janssen Pharmaceutical. Started Jun 2019; status: active, not recruiting.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03767244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03767244.